Treatment with LA-419 prevents monocrotaline-induced pulmonary hypertension and lung injury in the rat

M. Mourelle, M. T. Martin, F. Giménez

Research output: Contribution to journalArticleResearchpeer-review

1 Citation (Scopus)

Abstract

We evaluated the therapeutic potential of LA-419, a hybrid organic nitrate that donates nitric oxide and thiol groups, to improve pulmonary arterial hypertension in an experimental model induced by monocrotaline in the rat. Treatment with LA-419 from the first day after monocrotaline administration prevented the increase in pulmonary pressure as well as the increases in ventricle/body weight and pulmonary artery wall thickness. Administration of LA-419 after establishment of hypertensive status also resulted in an improvement of these parameters. Both preventive and therapeutic treatments reduced mortality. The antioxidant effect of LA-419 was comparable to that achieved with .-tocopherol. Pulmonary remodeling accomplished by LA-419 could be attributed to a balanced antioxidant effect associated with its nitric oxide/SH donor capability. Thus, LA-419 might represent a new therapeutic approach in severe pulmonary hypertension in humans.
Original languageEnglish
Pages (from-to)88-92
JournalProceedings of the Western Pharmacology Society
Volume54
Publication statusPublished - 1 Jan 2011

Fingerprint Dive into the research topics of 'Treatment with LA-419 prevents monocrotaline-induced pulmonary hypertension and lung injury in the rat'. Together they form a unique fingerprint.

Cite this